EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma

Corinna Kosnopfel iD, Tobias Sinnberg iD, Shrunal Mane, Michelle Dongo, Claus Garbe, Heike Niessner iD

International Journal of Molecular Sciences · 08.10.2025 · 26 (19) · 9794

DOI: 10.3390/ijms26199794 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.10.2025. Verfasst von Corinna Kosnopfel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Oncology and Pneumology, University Hospital Muenster, 48149 Münster, Germany. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Melanoma, Protein Kinase Inhibitors, MAP Kinase Signaling System. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small molecule inhibitors targeting BRAF mutations at V600 and downstream MEK represent a significant advancement in treating BRAF-mutant melanoma. However, resistance mechanisms, often involving reactivation of the MAPK pathway via ERK1/2, limit their efficacy. The ERK1/2 inhibitor ravoxertinib (GDC0994) was tested on melanoma cell lines with and without resistance to BRAFi or BRAFi + MEKi. Short-term assays evaluated cell viability, apoptosis induction, and pathway modulation via Western Blot, while long-term effects were assessed using a colony formation assay. Resistant and parental melanoma cells responded to long-term ERKi treatment with reduced growth, independent of sensitivity to BRAF or MEK inhibitors. Adding ERKi to BRAFi/MEKi significantly enhanced apoptosis and growth inhibition, particularly in resistant lines. Although ravoxertinib alone showed limited antitumor activity, its combination with BRAFi/MEKi yielded substantial benefits, especially in chronic settings. These findings suggest that combinatorial regimens incorporating ERK inhibitors represent a promising therapeutic strategy for BRAF-mutant melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins B-rafMelanomaProtein Kinase InhibitorsMAP Kinase Signaling SystemMutationHumansCell Line, TumorApoptosisCell ProliferationDrug Resistance, NeoplasmCell Survival

Stichwörter der Autor:innen

BRAF mutationERK inhibitorMAPK pathwaydrug resistancemelanoma therapy

Substanzen

Proto-Oncogene Proteins B-rafProtein Kinase InhibitorsBRAF protein, human

Autor:innen und Institutionen

  • Department of Hematology, Oncology and Pneumology, University Hospital Muenster, 48149 Münster, Germany.
  • Division of Dermatooncology, Department of Dermatology, University of Tuebingen, 72076 Tuebingen, Germany.
  • Cluster of Excellence iFIT (EXC 2180), 72076 Tuebingen, Germany.
  • Department of Dermatology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany.

ORCID-Profile: Corinna Kosnopfel, Tobias Sinnberg, Heike Niessner

Zitieren

APA

Kosnopfel, C., Sinnberg, T., Mane, S., Dongo, M., Garbe, C., & Niessner, H. (2025). Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma. International Journal of Molecular Sciences, 26(19), 9794. https://doi.org/10.3390/ijms26199794

Vancouver

Kosnopfel C, Sinnberg T, Mane S, Dongo M, Garbe C, Niessner H. Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma. International Journal of Molecular Sciences. 2025;26(19):9794. doi:10.3390/ijms26199794

BibTeX
@article{Kosnopfel2025,
  author = {Kosnopfel, Corinna and Sinnberg, Tobias and Mane, Shrunal and Dongo, Michelle and Garbe, Claus and Niessner, Heike},
  title = {Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant Melanoma},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {19},
  pages = {9794},
  doi = {10.3390/ijms26199794}
}
Kostenlos starten →